From $6,380 to $700,508: Adia pushes deeper into stem cell treatment

04/01/2026 – 10:07

Winter Park, Florida–(Newsfile Corp. – April 1, 2026) – Adia Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapy, and premium wellness solutions, today announced key highlights from its annual Form 10-K report for the year ended December 31, 2025. a dormant shell to an active player in the high-growth regenerative health sector.

By 2025, Adia Nutrition will achieve a total revenue of approx $700,508represents a substantial increase from just $6,380 in 2024. This growth is driven mainly by sales of biological products (approx 63%) and medical procedures (approx 35%) through Adia Labs and Adia Med divisions, with reduced reliance on supplement sales. Gross profit achieved $191,670While the company reported operating loss of $366,492 and net loss of $395,464. Management attributes the improved top-line performance to the launch of clinical services, increased sales of biologics, and initial R&D and clinical activities.

“Our 2025 results reflect the successful execution of our strategy to build a scalable platform in regenerative medicine,” said Larry Powalisz, Chief Executive Officer of Adia Nutrition. “Income grew more than 100-fold as we shifted our focus towards high-potential stem cells and biologic offerings. With our recent achievement of full SEC reporting status, we are now positioned for greater transparency, investor confidence, and accelerated growth towards potential uplisting.”

Key Business and Operational Highlights from the 10-K and Recent Developments:

• Regenerative Medicine Focus: Through Adia Med, the company offers specialty treatments including stem cell therapy for orthopedic conditions, pain management, and wound repair. Adia Med also supports autologous hematopoietic stem cell transplantation (AHSCT) for approved indications such as multiple sclerosis, and platelet-rich plasma therapy (PRP). Adia Labs procures and sells premium biological products like AdiaVita (umbilical cord blood derived stem cells and exosomes) and AdiaLink (amniotic fluid-derived exosomes), both processed in strict FDA Part 361 and AATB standards.

• Diversified Segment: The company operates through Adia Med (clinical services), Adia Labs (biological sales), and Biolete (nutritional supplements, including protein coffee and mushroom extract). It also holds an equity stake in a parallel nutrition business.

• Complete SEC Reporting Milestone: In February 2026, Adia’s Form 10 registration statement became effective, making the company a fully reporting entity under the Securities Exchange Act of 1934. This allows for regularly audited disclosures through 10-K, 10-Q, and 8-K filings, in accordance with standards to support NAS business.

• Operational Infrastructure: The company maintains a clinic and operations in Winter Park, Florida, with a small but focused team supplemented by medical experts on board, including doctors specializing in regenerative therapies.

• Market Opportunities: Adia is taking advantage of the growing stem cell therapy market, expected to achieve significant growth in the coming years, by emphasizing minimally manipulated allogeneic and autologous products.

The company notes that the ongoing investment in clinical protocols, staffing, equipment, and R&D, which contributes to higher operating expenses in 2025. Management expects annual operating costs in the range $450,000–$750,000 and anticipates continued revenue momentum while exploring additional capital sources as needed. The great uncertainty about the concern is expressed due to historical losses and reliance on financing, consistent with early-stage growth companies in the sector.

Adia Nutrition remains committed to innovation in personal health, bridging gaps in traditional systems with compassionate, science-backed regenerative solutions.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in the sale of stem cells and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billed wound care products. Adia is also expanding across the country with Adia Med clinics, specializing in orthopedics, pain management, and wound repair. Adia Med Clinic also offers specialized regenerative treatments such as stem cell therapy and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.

Revenue is generated by service fees, product sales, equity stakes, and billing insurance for health care. In addition, Adia Nutrition Inc. investing in parallel businesses such as Cement Factory LLC, a nutrition and supplement company with shared values ​​and a focus on health and wellness. Through strong partnerships with high-level medical entities and unwavering dedication to standardization, FDA-approved lab protocols, Adia Nutrition Inc. revolutionizing health care, igniting a national movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are forward-looking statements based on current plans and management expectations and are subject to several uncertainties and risks that may significantly affect the company’s current operating results and financial expectations. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statement can be found in reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290856

FAQ

What will be Adia Nutrition’s (ADIA) revenue and profit figures in 2025?

Adia reports $700,508 income for 2025, with a gross profit of $191,670. According to the company, the operating loss $366,492 and net loss $395,464 for years.

When will Adia Nutrition (ADIA) become a fully reporting SEC company and what does that mean?

Adia becomes a full reporting company at February 2026. According to the company, this enables regularly audited 10-K, 10-Q, and 8-K disclosures and supports future NASDAQ uplisting efforts.

How will Adia Nutrition (ADIA) achieve 2025 revenue growth and segment mix?

Revenue growth was driven by biologics and clinical services, with approx 63% of biological products and 35% of medical procedures. According to the company, sales from Adia Labs and Adia Med led to the increase.

What risks did Adia Nutrition (ADIA) disclose in its 2025 Form 10-K?

The company disclosed substantial doubt about going to concern due to historical losses and financing reliance. According to the company, continued capital needs and early-stage operating losses present a material risk to operations.

What are Adia Nutrition’s (ADIA) operating expenses and cash needs for 2026?

Management expects annual operating costs of $450,000–$750,000 in the near term. According to the company, it will continue to invest in R&D, staffing, and clinical protocols while exploring additional sources of capital.

How might Adia Nutrition’s (ADIA) SEC reporting status affect investors and potential uplisting?

SEC reporting can improve transparency and investor confidence, aligning filings with major exchange standards. According to the company, this status supports potential NASDAQ uplisting efforts in the future, subject to meeting the exchange’s requirements.